• PTX3-TLR4/NF-κB-FGF21 Axis in Glucocorticoid-Induced ONFH

  2026-04-27

  Li et al. elucidate how pentraxin 3 (PTX3) protects against glucocorticoid-induced osteonecrosis of the femoral head (ONFH) by modulating the TLR4/NF-κB/FGF21 signaling axis. This mechanistic insight reveals new intervention points for bone metabolism research and highlights the relevance of PKC/NF-κB pathway inhibitors in dissecting osteogenic regulation.

• Risedronate Sodium: FPPS Inhibitor Workflow for Bone Researc

  2026-04-27

  Risedronate Sodium, a potent FPP synthase inhibitor, advances bone metabolism research through diverse delivery systems and robust anti-resorptive efficacy. Explore optimized experimental workflows, comparative innovations, and troubleshooting grounded in recent nanopatch delivery breakthroughs.

• NF 340: Transforming P2Y11 Antagonist Use in Cancer Research

  2026-04-26

  NF 340, a highly selective P2Y11 antagonist, empowers researchers to dissect GPCR signaling with unmatched specificity—especially in cancer invasiveness and immunology workflows. This guide details hands-on protocol strategies, troubleshooting insights, and the translational leap enabled by NF 340, referencing breakthrough findings in breast cancer cell migration.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-25

  Schwartz's dissertation introduces a refined framework for distinguishing between proliferative arrest and cell death in anti-cancer drug testing. By clarifying the interpretation of in vitro assay metrics, the study informs more accurate preclinical evaluation and translational decision-making.

• RBMS1 Loss Enhances Anti-Tumor Immunity in Triple-Negative B

  2026-04-24

  This study identifies the RNA-binding protein RBMS1 as a key regulator of PD-L1 stability in triple-negative breast cancer (TNBC). Its loss enhances anti-tumor immunity by promoting PD-L1 degradation, offering a novel immunotherapeutic target for improving checkpoint blockade efficacy.

• H-89: Applied cAMP-Dependent Protein Kinase Inhibitor Workfl

  2026-04-24

  H-89 delivers precise, selective inhibition of protein kinase A—empowering researchers to dissect cAMP signaling in bone, metabolic, and apoptosis assays. See how recent breakthroughs in metabolic bone research translate into optimized experimental design and troubleshooting for robust, reproducible results.

• Rotigotine’s Dual Impact: Dopaminergic Modulation and Bladde

  2026-04-23

  Explore how Rotigotine, a potent dopamine D2/D3 receptor agonist, uniquely advances Parkinson’s disease research by elucidating both motor and non-motor symptom pathways. This article delivers a deep dive into novel neuro-urological insights, mechanistic findings, and advanced assay strategies unavailable in standard guides.

• Fluorouracil (Adrucil) in Solid Tumor Research: Optimized Wo

  2026-04-23

  Fluorouracil (Adrucil) empowers precise inhibition of DNA replication in colon and breast cancer research, backed by reproducible cytotoxicity benchmarks and advanced protocol guidance. This article delivers actionable workflows, troubleshooting insights, and the latest translational applications—anchored by peer-reviewed evidence and APExBIO’s trusted supply.

• Mitoxantrone HCl: DNA Topoisomerase II Inhibitor Workflows

  2026-04-22

  Mitoxantrone HCl stands out as a dual-action DNA topoisomerase II inhibitor for both cytotoxicity and nuclear receptor modulation, enabling advanced research in cancer biology and beyond. This article delivers actionable workflows, troubleshooting guidance, and a synthesis of recent breakthroughs for maximizing assay performance with this APExBIO reagent.

• Propranolol: Mechanistic Insights and Strategic Impact in Tr

  2026-04-22

  This article presents a thought-leadership perspective on Propranolol, a non-selective β-adrenergic receptor blocker, focusing on its mechanistic actions, translational significance, and experimental best practices for researchers. Integrating recent meta-analytic evidence, competitive intelligence, and workflow guidance, we highlight how Propranolol (SKU: BA1217) from APExBIO enables innovative research avenues in cardiovascular, neuropsychiatric, and metabolic domains.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-04-21

  Schwartz's dissertation introduces a critical distinction between relative viability and fractional viability in in vitro cancer drug testing, enabling more precise interpretation of anti-cancer compound effects. This approach clarifies the interplay between proliferation arrest and apoptosis, improving the reliability of preclinical drug evaluation.

• Translating TGF-β Dual Inhibition: LY2109761 in Cancer Model

  2026-04-21

  This thought-leadership article provides a mechanistic and strategic roadmap for translational researchers leveraging LY2109761—a potent TGF-β receptor type I and II dual inhibitor—in advanced cancer and fibrosis models. Integrating cutting-edge insights from recent literature, including the role of TGF-β in stem cell plasticity and tumor progression, we explore experimental design, comparative positioning, and translational potential. The discussion advances beyond standard product summaries, offering actionable guidance and evidence-based protocol parameters, while directly linking to authoritative resources and peer-reviewed findings.

• Ultrafiltration Enables High-Purity Circular RNA for Therape

  2026-04-20

  Guillen-Cuevas et al. establish ultrafiltration as a high-yield, high-purity method for isolating circular RNA from linear RNA contaminants. This work addresses a critical bottleneck in circRNA manufacturing, supporting the development of more stable RNA therapeutics.

• VNERi: A Superior Index for Septic Shock Severity Assessment

  2026-04-20

  A recent analysis introduces the VNERi index—diastolic arterial pressure adjusted for heart rate and norepinephrine dose—as a more robust predictor of outcomes in early septic shock than traditional hemodynamic markers. This approach offers actionable insight for guiding vasopressor therapy and highlights the importance of accurately modeling adrenergic signaling in translational research.

• HR Defects Predict Olaparib Sensitivity in Mesothelioma Cell

  2026-04-19

  Borchert et al. (2019) leveraged gene expression profiling to reveal that defects in homologous recombination repair (HRR)—termed "BRCAness"—predict increased apoptosis and senescence in malignant pleural mesothelioma (MPM) cells upon olaparib treatment. Their findings highlight new biomarkers and therapeutic strategies for a cancer type with poor prognosis, offering a foundation for precision medicine approaches.

15092 records 1/1007 page Next 12345 下5页 Last page